DrugDashboards

Medroxyprogesterone Acetate

Medroxyprogesterone acetate · MEDROXYPROGESTERONE ACETATE 150 mg/mL · Injection, Suspension, Extended Release · Intramuscular · Amphastar Pharmaceuticals, Inc.

NDC 00548-5701-00 · 1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price is down 14% over the past year, to $28.49 per mL. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$28.49per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$56.81per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$22.61per package of 1MLAmphastar Pharmaceuticals, Inc. · Sep 15, 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$50.00$100.00Feb 2018Sep 2026$28.49
103 price points · per MLSource: CMS NADAC

Medicaid spend (2025)

$1.4M
32,096 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

40● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for medroxyprogesterone acetate (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $22.00 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA077334
TE code
AB
Approval date
Nov 28, 2017
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Medroxyprogesterone acetate (Injection, Suspension, Extended Release)

LabelerStrengthFirst seenLast seen
Amphastar Pharmaceuticals, Inc.MEDROXYPROGESTERONE ACETATE 150 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Medroxyprogesterone Acetate — NDC 00548-5701-00," retrieved September 3, 2026, https://drugdashboards.com/drug/00548570100.

Free to cite with attribution — see how the data is put together.